RU2008110644A - Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств - Google Patents

Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств Download PDF

Info

Publication number
RU2008110644A
RU2008110644A RU2008110644/15A RU2008110644A RU2008110644A RU 2008110644 A RU2008110644 A RU 2008110644A RU 2008110644/15 A RU2008110644/15 A RU 2008110644/15A RU 2008110644 A RU2008110644 A RU 2008110644A RU 2008110644 A RU2008110644 A RU 2008110644A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
indole
cooh
imidazole
general formula
Prior art date
Application number
RU2008110644/15A
Other languages
English (en)
Other versions
RU2373934C1 (ru
Inventor
Владимир Евгеньевич Небольсин (RU)
Владимир Евгеньевич Небольсин
Дмитрий Сергеевич Блинов (RU)
Дмитрий Сергеевич Блинов
Владимир Павлович Балашов (RU)
Владимир Павлович Балашов
Татьяна Александровна Кромова (RU)
Татьяна Александровна Кромова
Галина Александровна Желтухина (RU)
Галина Александровна Желтухина
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" (Ru)
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" (Ru), Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез" (Ru)
Priority to RU2008110644/15A priority Critical patent/RU2373934C1/ru
Priority to UAA201012323A priority patent/UA104420C2/ru
Priority to PCT/RU2009/000133 priority patent/WO2009116896A1/ru
Priority to EA201071098A priority patent/EA018127B1/ru
Priority to US12/922,958 priority patent/US20110224213A1/en
Publication of RU2008110644A publication Critical patent/RU2008110644A/ru
Application granted granted Critical
Publication of RU2373934C1 publication Critical patent/RU2373934C1/ru
Priority to US13/961,019 priority patent/US8912185B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1. Применение соединений общей формулы (I): ! ! где R1 = имидазол, индол, ! R2 = COOH, H, ! или его фармацевтически приемлемой соли в качестве противоаритмического средства. ! 2. Применение соединений общей формулы (I): ! ! где R1 = имидазол, индол, ! R2 = COOH, H, ! или его фармацевтически приемлемой соли для получения лекарственного средства, обладающего противоаритмической активностью. ! 3. Фармацевтическая композиция, обладающая противоаритмической активностью, содержащая соединение общей формулы (I): ! ! где R1 = имидазол, индол, ! R2 = COOH, H, ! или его фармацевтически приемлемую соль в эффективном количестве и фармацевтически приемлемый носитель. ! 4. Лекарственное средство, обладающее противоаритмической активностью, содержащее соединение общей формулы (I): ! ! где R1 = имидазол, индол, ! R2 = COOH, H, ! или его фармацевтически приемлемую соль. ! 5. Способ лечения аритмии, включающий введение млекопитающему эффективного количества соединения общей формулы (I): ! ! где R1 = имидазол, индол, ! R2 = COOH, H, ! или его фармацевтически приемлемой соли.

Claims (5)

1. Применение соединений общей формулы (I):
Figure 00000001
где R1 = имидазол, индол,
R2 = COOH, H,
или его фармацевтически приемлемой соли в качестве противоаритмического средства.
2. Применение соединений общей формулы (I):
Figure 00000001
где R1 = имидазол, индол,
R2 = COOH, H,
или его фармацевтически приемлемой соли для получения лекарственного средства, обладающего противоаритмической активностью.
3. Фармацевтическая композиция, обладающая противоаритмической активностью, содержащая соединение общей формулы (I):
Figure 00000001
где R1 = имидазол, индол,
R2 = COOH, H,
или его фармацевтически приемлемую соль в эффективном количестве и фармацевтически приемлемый носитель.
4. Лекарственное средство, обладающее противоаритмической активностью, содержащее соединение общей формулы (I):
Figure 00000001
где R1 = имидазол, индол,
R2 = COOH, H,
или его фармацевтически приемлемую соль.
5. Способ лечения аритмии, включающий введение млекопитающему эффективного количества соединения общей формулы (I):
Figure 00000001
где R1 = имидазол, индол,
R2 = COOH, H,
или его фармацевтически приемлемой соли.
RU2008110644/15A 2008-03-19 2008-03-19 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств RU2373934C1 (ru)

Priority Applications (6)

Application Number Priority Date Filing Date Title
RU2008110644/15A RU2373934C1 (ru) 2008-03-19 2008-03-19 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
UAA201012323A UA104420C2 (ru) 2008-03-19 2009-03-18 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
PCT/RU2009/000133 WO2009116896A1 (ru) 2008-03-19 2009-03-18 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
EA201071098A EA018127B1 (ru) 2008-03-19 2009-03-18 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
US12/922,958 US20110224213A1 (en) 2008-03-19 2009-03-18 Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents
US13/961,019 US8912185B2 (en) 2008-03-19 2013-08-07 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2008110644/15A RU2373934C1 (ru) 2008-03-19 2008-03-19 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств

Publications (2)

Publication Number Publication Date
RU2008110644A true RU2008110644A (ru) 2009-09-27
RU2373934C1 RU2373934C1 (ru) 2009-11-27

Family

ID=41091132

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008110644/15A RU2373934C1 (ru) 2008-03-19 2008-03-19 Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств

Country Status (5)

Country Link
US (2) US20110224213A1 (ru)
EA (1) EA018127B1 (ru)
RU (1) RU2373934C1 (ru)
UA (1) UA104420C2 (ru)
WO (1) WO2009116896A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382179A (zh) * 2013-06-05 2013-11-06 四川百利药业有限责任公司 英加韦林的多晶型物及其制备方法
RU2546002C1 (ru) * 2014-01-20 2015-04-10 Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" Фармацевтическая композиция в форме таблетки и способ ее получения
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
EP3126838B1 (en) * 2014-04-03 2017-11-01 Koninklijke Philips N.V. High sensitive detection of melatonin
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN113861096B (zh) * 2021-10-19 2023-07-18 中国农业大学 含吲哚结构的化合物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1206275A1 (ru) * 1982-10-25 1986-01-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Динатриева соль 2-(2,6-диметил-3,5-диэтоксикарбонил-1,4-дигидропиридин-4-карбоксамидо)глутаровой кислоты,обладающа антиаритмической активностью
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
RU2335495C2 (ru) 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств

Also Published As

Publication number Publication date
UA104420C2 (ru) 2014-02-10
EA018127B1 (ru) 2013-05-30
RU2373934C1 (ru) 2009-11-27
WO2009116896A1 (ru) 2009-09-24
US20130324540A1 (en) 2013-12-05
EA201071098A1 (ru) 2011-02-28
US20110224213A1 (en) 2011-09-15
US8912185B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
ES2540853T3 (es) Sales de dicetopiperazina para la administración de fármacos
RU2008110644A (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2010265321A5 (ru)
JP2010530431A5 (ru)
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
JP2012512907A5 (ru)
JP2015506989A5 (ru)
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
UA107324C2 (uk) Похідні 1,2,3-триазолу для застосування як інгібіторів стеароїл-coa десатурази
JP2013518036A5 (ru)
JP2013540114A5 (ru)
BRPI0409809A (pt) formulação farmacêutica do sal de sódio de telmisartano
JP2009500441A5 (ru)
JP2017533964A5 (ru)
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
RU2007132179A (ru) Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
JP2015522033A5 (ru)
SE0002476D0 (sv) New compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200320